You need JavaScript to view this

Union of {sup 99m} Tc-HYNIC-TOC at the somatostatin receptors in cells of pancreas cancer; Union del {sup 99m} Tc-HYNIC-TOC a los receptores de somatostatina en celulas de cancer de pancreas

Abstract

The radiation toxic effects have been used in therapy however much 50 years. The absorbed radiation dose can be determined at cellular level using cancerous cell cultures. If the deposited In vitro radiation dose coming from similar activities of several therapeutic radiopharmaceuticals it can compare it will be possible to choose the therapeutic radiopharmaceutical that it offers better dosimetric characteristics for the patient. The objective of this original investigation was to determine the union percentage of the octreotide {sup 99m}Tc-HYNlC-TOC to the somatostatin receivers in cells of cancer pancreas as well as the internalization, externalization and cellular viability. It was used the octapeptide, (octreotide, TOC) labelled with {sup 99m}Tc by means of the HYNIC chelating agent (6-hydrazine pyridine-3-carboxylic acid) and 3 cellular lines of murine pancreas cancer (AR42J), of cancer of human pancreas (CAPAN) and of one negative cellular line for somatostatin receivers (WRL-68). The {sup 99m}Tc-HYNIC-TOC was compared against two negative proofs for somatostatin receivers: the peptide {sup 99m}Tc-UBI and the {sup 99m}TcO{sub 4}. The cellular lines were conserved in the synthetic media Dulbecco-Eagle. After 2, 4 and 24 h of exhibition to the radiation, the cells are picked up and its are determined the viability by count in  More>>
Authors:
Rodriguez C, J; [1]  Ramirez I, M T; [2]  Ferro F, G; Pedraza L, M [3] 
  1. Facultad de Medicina, UAEM, 50000 Toluca, Estado de Mexico (Mexico)
  2. INCMNSZ, Vasco de Quiroga Num. 15, Tlalpan, 14000 Mexico D.F. (Mexico)
  3. ININ, 52045 Ocoyoacac, Estado de Mexico (Mexico)
Publication Date:
Jul 01, 2005
Product Type:
Conference
Report Number:
INIS-MX-2294
Resource Relation:
Conference: 39. National Congress of Nuclear Medicine, Tuxtla Gutierrez, Chiapas (Mexico), 4-7 May 2005
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; CELL CULTURES; DIAGRAMS; EXPERIMENTAL DATA; IN VITRO; LABELLED COMPOUNDS; PANCREAS; PATIENTS; PEPTIDES; RADIATION DOSES; RADIOPHARMACEUTICALS; SOMATOSTATIN; TECHNETIUM 99; TIME DEPENDENCE
OSTI ID:
20926423
Research Organizations:
Sociedad Mexicana de Medicina Nuclear A.C., Mexico D.F. (Mexico); MIYMSA, Medidores Industriales y Medicos, S.A. de C.V. (Mexico)
Country of Origin:
Mexico
Language:
Spanish
Other Identifying Numbers:
TRN: MX0700327085196
Availability:
Available from INIS in electronic form
Submitting Site:
MXN
Size:
10 pages
Announcement Date:
Sep 29, 2007

Citation Formats

Rodriguez C, J, Ramirez I, M T, Ferro F, G, and Pedraza L, M. Union of {sup 99m} Tc-HYNIC-TOC at the somatostatin receptors in cells of pancreas cancer; Union del {sup 99m} Tc-HYNIC-TOC a los receptores de somatostatina en celulas de cancer de pancreas. Mexico: N. p., 2005. Web.
Rodriguez C, J, Ramirez I, M T, Ferro F, G, & Pedraza L, M. Union of {sup 99m} Tc-HYNIC-TOC at the somatostatin receptors in cells of pancreas cancer; Union del {sup 99m} Tc-HYNIC-TOC a los receptores de somatostatina en celulas de cancer de pancreas. Mexico.
Rodriguez C, J, Ramirez I, M T, Ferro F, G, and Pedraza L, M. 2005. "Union of {sup 99m} Tc-HYNIC-TOC at the somatostatin receptors in cells of pancreas cancer; Union del {sup 99m} Tc-HYNIC-TOC a los receptores de somatostatina en celulas de cancer de pancreas." Mexico.
@misc{etde_20926423,
title = {Union of {sup 99m} Tc-HYNIC-TOC at the somatostatin receptors in cells of pancreas cancer; Union del {sup 99m} Tc-HYNIC-TOC a los receptores de somatostatina en celulas de cancer de pancreas}
author = {Rodriguez C, J, Ramirez I, M T, Ferro F, G, and Pedraza L, M}
abstractNote = {The radiation toxic effects have been used in therapy however much 50 years. The absorbed radiation dose can be determined at cellular level using cancerous cell cultures. If the deposited In vitro radiation dose coming from similar activities of several therapeutic radiopharmaceuticals it can compare it will be possible to choose the therapeutic radiopharmaceutical that it offers better dosimetric characteristics for the patient. The objective of this original investigation was to determine the union percentage of the octreotide {sup 99m}Tc-HYNlC-TOC to the somatostatin receivers in cells of cancer pancreas as well as the internalization, externalization and cellular viability. It was used the octapeptide, (octreotide, TOC) labelled with {sup 99m}Tc by means of the HYNIC chelating agent (6-hydrazine pyridine-3-carboxylic acid) and 3 cellular lines of murine pancreas cancer (AR42J), of cancer of human pancreas (CAPAN) and of one negative cellular line for somatostatin receivers (WRL-68). The {sup 99m}Tc-HYNIC-TOC was compared against two negative proofs for somatostatin receivers: the peptide {sup 99m}Tc-UBI and the {sup 99m}TcO{sub 4}. The cellular lines were conserved in the synthetic media Dulbecco-Eagle. After 2, 4 and 24 h of exhibition to the radiation, the cells are picked up and its are determined the viability by count in a Neubauer camera using tripan blue. In the same times it was calculated the union percentage of the radiopharmaceutical to the cells and the internalization (union to the cytoplasm) and the externalization (union to membrane receivers). With those figures it was calculated the absorbed radiation dose at cellular level. Results: At 4 hours the union percentage of the {sup 99m}Tc-HYNlC-TOC to the AR42-J cells was 6.83 times greater than for the WRL-68 control cells of human papilloma, (without receivers of the somatostatin) and for the CAPAN them 4 times greater than for the same cells used as negative control, for the case of the {sup 99m}Tc-UBI and the {sup 99m}TcO{sub 4} one doesn't observe a significant difference and the percentage of viability of the AR42-J cells due by the {sup 99m}Tc-HYNlC-TOC it was 20% smaller in comparison with {sup 99m}Tc-UBI and {sup 99m}TcO{sub 4}. The internalization percentage of the AR42-J cells was of 43.28 {+-}1.62 due to the somatostatin receivers that its enter together with the radiopharmaceutical at the interior of the cell and 56.72 {+-}3.25 are together to the cellular membrane. (Author)}
place = {Mexico}
year = {2005}
month = {Jul}
}